Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PSMG3 | Q9BT73 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18090614 | 0.85 | TDP1 (0.38) | IMPDH2TDP1CYP3A4MAPTPSMG3 | |
| SCHEMBL2798555 | 0.81 | TDP1 (0.39) | IMPDH2TDP1PTGS2CYP3A4MAPT | |
| SCHEMBL5516691 | 0.81 | TDP1 (0.39) | IMPDH2TDP1PTGS2CYP3A4MAPT | |
| SCHEMBL1052797 | 0.81 | TDP1 (0.39) | IMPDH2TDP1PTGS2CYP3A4MAPT | |
| SCHEMBL12143217 | 0.81 | TDP1 (0.46) | IMPDH2TDP1PTGS2CYP3A4MAPT | |
| SCHEMBL2952712 | 0.80 | ACHE (0.40) | TDP1CYP3A4MAPTCA1CA2 | |
| SCHEMBL14089301 | 0.80 | TDP1 (0.40) | IMPDH2TDP1PTGS2CYP3A4MAPT | |
| SCHEMBL5587645 | 0.80 | IMPDH2 (0.39) | IMPDH2TDP1CYP3A4MAPTPSMG3 | |
| SCHEMBL14511736 | 0.79 | MGAM (0.36) | IMPDH2TDP1PTGS2CYP3A4MAPT | |
| SCHEMBL14511732 | 0.79 | IMPDH2 (0.33) | IMPDH2TDP1PTGS2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786828-B1 | NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY | BIOMERIEUX SA (FR) | 2012-01-11 | — | — | EP | disclosed |
| US-7932050-B2 | Enzymatic substrates derived from phenoxazinone and their use as developers in detection of microorganisms with peptidase activity | BIOMERIEUX (FR) | 2011-04-26 | — | — | US | disclosed |
| US-20100028926-A1 | Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity | BIOMERIEUX (FR) | 2010-02-04 | — | — | US | disclosed |
| US-7626018-B2 | Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity | bioMérieux (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20080293094-A1 | Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity | BIOMERIEUX (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1786828-A1 | NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY | BIOMERIEUX (FR) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006030119-A1 | NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY | bioMérieux (FR) | 2006-03-23 | — | — | WO | disclosed |
| EP-0549366-B1 | Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses | SANKYO CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| EP-0549365-B1 | Thiazolidine compounds, their preparation and their therapeutic uses | SANKYO CO (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5338855-A | Treating diabetes or hyperlipemia | SANKYO COMPANY, LIMITED (JP) | 1994-08-16 | — | — | US | disclosed |
| EP-0549366-A1 | Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0549365-A1 | Thiazolidine compounds, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293094-A1 | Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity | PEPD, CTRL, PREP | IMPDH2 1385/4885TDP1 1131/4885PTGS2 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.